RxDoctor Payments Data

Harish Guddati, MD

Gastroenterology · Bronx, NYNPI 1891040911

Payments from drug & device makers

$2,689in general payments, 2019–2025

Across 115 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$516
  • Takeda Pharmaceuticals U.S.A., Inc.$469
  • Bristol Myers Squibb$266
  • Conmed Corporation$110
  • Lilly USA, LLC$101
  • plus $209 from 6 others

What the payments were for

  • Food & beverage$2,60497%
  • Education$853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,689 in reported general payments places this provider in the 50th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$94,270
Medicare patients
332
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab23$619,052
RinvoqUpadacitinib14$246,846
LinzessLinaclotide114$70,599
XeljanzTofacitinib Citrate11$62,602
Mesalamine117$47,330
Mesalamine DrMesalamine14$4,439
Dexlansoprazole DrDexlansoprazole19$4,170
Lubiprostone14$3,863
Omeprazole440$3,329
Pantoprazole Sodium262$1,772
Mesalamine ErMesalamine15$1,654
Famotidine169$1,507
Colestipol Hcl57$1,369
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl91$1,320
Dicyclomine Hcl101$1,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$516$619,05223 claims
AbbVieRinvoq, Linzess$1,018$317,445128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →